1 Introduction The idea that substances produced by duodenal mucosa could stimulate and initiate pancreatic endocrine, thereby reducing the amount of urinary glucose in patients with diabetes, was first proposed in 1906 (Moore, 1906)
An Z, Prigeon RL, DAlessio DA: Improved glycemic control enhances the incretin effect in patients with type 2 diabetes
4.6% in the non-GLP-1 group Significantly lower rates of acute myocardial infarction Lower risk of major adverse cardiac events overall Psoriatic arthritis already raises cardiovascular risk substantially
Why Some Patients See Faster Results While every patient benefits from GLP 1 therapy, certain physiological and lifestyle factors can create quicker or more noticeable early progress
One placebo-controlled trial, called ATTAIN-MAINTAIN, followed adults who had previously completed the SURMOUNT-5 obesity trial, a randomized controlled study evaluating whether tirzepatide, the active ingredient in Zepbound, led to greater body weight reduction versus semaglutide in adults with obesity
Lo mismo ocurre con los hidratos de carbono
